Cytosorbents Seeks FDA Approval for Blood Purification Device in Second Attempt
Published on 03/12/2026 at 01:17 | Redaktion boerse-global.de
The coming weeks are critical for Cytosorbents as the company prepares a renewed regulatory push in the United States. Following setbacks last year, the firm is finalizing a new submission for its DrugSorb-ATR blood purification system. This represents a pivotal second chance to secure a foothold in the valuable U.S. market.
Financial Milestones and Upcoming Report
Alongside its regulatory strategy, the company is sharply focused on improving its financial performance. Management has set a target to reach operational cash flow breakeven by the end of the first quarter of 2026. A cost-reduction initiative and workforce reductions implemented the previous year are intended to support this goal.
Investors will soon receive a clearer picture of the financial situation. The company is scheduled to release its fourth quarter and full-year 2025 results on Wednesday, March 25. A subsequent webcast will feature management discussing the financial statements and providing an updated business outlook.
The Path to U.S. Market Clearance
The device, designed to reduce bleeding during cardiac surgery, previously encountered regulatory obstacles with the U.S. Food and Drug Administration (FDA). An initial application for approval was rejected in April 2025, and a subsequent appeal failed in August of the same year. While the agency requested additional efficacy data, it emphasized that the device raised no safety concerns.
Should investors sell immediately? Or is it worth buying Cytosorbents?
The current plan involves submitting an updated application by the end of the ongoing first quarter of 2026. This new filing will incorporate real-world clinical data alongside findings from the STAR-T study. A decision from the regulatory body is anticipated by mid-2026.
Ad
Cytosorbents Stock: New Analysis - 12 March
Fresh Cytosorbents information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
